Skip to main content
SpringerLink
Log in

Control of prolactin secretion

  • Review
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

  1. 1.

    Prolactin is a 21,500 Dalton single-chain polypeptide hormone but may occur in 50 kDa and 150 kDa molecular variants.

  2. 2.

    These large PRL variants may be secreted predominantly; this condition is termed “macroprolactinemia”. It is characterized by high immunological and normal biological serum levels of prolactin, and lack of clinical symptoms of hyperprolactinemia.

  3. 3.

    The information on PRL is encoded on chromosome 6. Transcription can be enhanced and suppressed by a variety of hormonal factors.

  4. 4.

    PRL is secreted in a pulsatile fashion; it displays a circadian rhythm (with a maximum during sleep) and is stimulated by some amino acids. PRL also responds to mechanical stimulation of the breast.

  5. 5.

    PRL rises during pregnancy, and maintainance of hyperprolactinemia (and, thereby, physiological infertility) is dependent on the frequency and duration of breast feedings.

  6. 6.

    Hypothalamic regulation of prolactin mainly involves tonic inhibition via portal dopamine. The physiological importance of various stimulating factors present in the hypothalamus is still incompletely understood. In particular, there is still no place for TRH in PRL physiology.

  7. 7.

    PRL is released in response to stress; this response may be mediated by opioids. The low-estrogen, low-gonadotropin amenorrhea of endurancetraining women is not mediated by prolactin, however.

  8. 8.

    Estrogens stimulate PRL gene transcription via at least two independent mechanisms. There are many clinical examples of this estrogen effect on prolactin serum levels, and also on the growth of prolactinomas.

  9. 9.

    Mild hyperprolactinemia remains an enigma which cannot satisfactorily be resolved by biochemical or radiological testing. The border between “normal” and “elevated” prolactin is illdefined. The possibility of macroprolactinemia complicates this matter even further.

  10. 10.

    The number of drugs which suppress prolactin by acting on pituitary D2 receptors, and which are useful in the treatment of hyperprolactinemia, continues to increase. In the field of ergot alkaloids, parenteral application appears to be a logical solution to the problem of the high first-pass effect; in addition, this form of treatment is frequently better tolerated than the oral route.

  11. 11.

    Prolactinoma development is presently being studied employing molecular biological techniques; the question of whether tumorigenesis can be attributed to specific defects of gene regulation remains to be answered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

PRL:

prolactin

rPRL:

rat prolactin

mRNA:

messenger ribonucleic acid

DNA:

desoxyribonucleic acid

MEA:

multiple endocrine adenomatosis

TRH:

thyreotropin releasing hormone

VIP:

vasoactive intestinal peptide

kDa:

kilodalton

EGF:

epidermal growth factor

References

  1. Adler S, Waterman ML, He X, Rosenfeld MG (1988) Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain. Cell 52:685–695

    Article  CAS  PubMed  Google Scholar 

  2. Ahmed SR, Shalet SM (1986) Discordant responses of prolactinoma to two different dopamine agonists. Clin Endocrinol (Oxf) 24:421–426

    Article  CAS  Google Scholar 

  3. Allolio B, Höppner A, Leonhardt U, Deuss U, Winkelmann W (1987) Size heterogeneity of immunoreactive prolactin in patients with prolactinoma. Acta Endocrinol (Copenh) 114:475–482

    CAS  Google Scholar 

  4. Andersen AN, Tabor A (1982) PRL, TSH, GH and LH responses to metoclopramide and breast feeding in normal and hyperprolactinemic women. Acta Endocrinol (Copenh)100:177

    CAS  Google Scholar 

  5. Anderson AN, Pedersen H, Djursing H, Anderson BN, Friesen HG (1982) Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception. Fertil Steril 38:625–628

    Article  Google Scholar 

  6. Bachstrom CT, McNeilly AS, Leask RM, Baird DT (1982) Pulsatile secretion of LH, FSH, prolactin, estradiol and progesterone during the human menstrual cycle. Clin Endocrinol (Oxf) 17:29–42

    Article  Google Scholar 

  7. Barton AC, Lahti RA, Piercey MF, Moore KE (1989) Autoradiographic identification of prolactin binding sites in rat median eminence. Neuroendocrinology 49:649–653

    Article  CAS  PubMed  Google Scholar 

  8. Benker G, Gieshoff G, Freundlieb O, Windeck R, Schulte HM, Reinwein D (1986) Parenteral bromocriptine in the treatment of hormonally active pituitary tumors. Clin Endocrinol 24:505

    Article  CAS  Google Scholar 

  9. Bevan JS, Burke CW, Esiri MM, Adams CBT (1987) Misinterpretation of prolactin levels leading to management errors in patients with sella enlargement. Am J Med 82:29–32

    Article  CAS  PubMed  Google Scholar 

  10. Biasioli S, d'Andrea G, Micieli G, Feriani M, Bron D, Chiaramonte S, Cananzi A, La Greca G (1987) Hyperprolactinemia as a marker of neurotransmitter imbalance in uremic population. Int J Artif Organs 10:245–257

    CAS  PubMed  Google Scholar 

  11. Boyar RM, Kapen S, Finkelstein JW, Parlow M, Sassin JF, Fukushima DK, Weitzman ED, Hellman L (1974) Hypothalamic pituitary function in diverse hyperprolactinemic states. J Clin Invest 53:1588

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Brenner SH, Lessing JB, Quagliarello J, Weiss G (1985) Hyperprolactinemia and associated pituitary prolactinomas. Obstet Gynecol 65:661–664

    CAS  PubMed  Google Scholar 

  13. Bricaire C, Kerlan Y, Kutten F, Mauvais-Jarvis P (1988) La grossesse: une modalité de guérison des adénomes à prolactine? Presse Med 17:2117–2119

    CAS  PubMed  Google Scholar 

  14. Brisson GR, Peronnet F, Dedoux M, Pellerin-Massicotte J, Matton P, Garceau F, Boisvert P (1986) Temperature-induced hyperprolactinemia during exercise. Horm Metab Res 18:283–284

    Article  CAS  PubMed  Google Scholar 

  15. Brown SB, Murphy IK, Enzman DR (1983) CT characteristics of the normal pituitary gland. Neuroradiology 24:259–262

    Article  CAS  PubMed  Google Scholar 

  16. Camanni F, Ciccarelli E, Ghigo E, Müller EE (1989) Hyperprolactinemia: neuroendocrine and diagnostic aspects. J Endocrinol Invest 12:653–668

    Article  CAS  PubMed  Google Scholar 

  17. Carillo AJM, Pool TB, Sharp ZD (1985) Vasoactive intestinal peptide increases prolactin messenger ribonucleic acid content in GH3 cells. Endocrinology 115:202–206

    Article  Google Scholar 

  18. Carlson HE, Levine GA, Goldberg NJ, Hershman JM (1978) Hyperprolactinemia in multiple endocrine adenomatosis type I. Arch Int Med 138:1807–1808

    Article  CAS  Google Scholar 

  19. Carlson HE (1989) Prolactin stimulation by protein is mediated by amino acids in humans. J Clin Endocrinol Metab 69:7–14

    Article  CAS  PubMed  Google Scholar 

  20. Clarks IJ, Cummins JT (1987) Pulsatility of reproductive hormones: physiological basis and clinical implications. Baillieres Clin Endocrinol Metab 1:1–21

    Article  Google Scholar 

  21. Collu R, Bouvier C, Lagace G (1988) Selective deficiency of guanine nucleotide-binding protein Go in two dopamine-resistant pituitary tumors. Endocrinology 122:1176–1178

    Article  CAS  PubMed  Google Scholar 

  22. Copeland PM, Bartin JB, Ridgeway EC (1986) Cysteamine decreases prolactin responsiveness to thyrotropin-releasing hormone in normal men. Am J Med Sci 291:16–19

    Article  CAS  PubMed  Google Scholar 

  23. Corenblum B, Taylor PJ (1988) Idiopathic hyperprolactinemia may include a distinct entity with a natural history different from that of prolactin adenomas. Fertil Steril 49:544–546

    Article  CAS  PubMed  Google Scholar 

  24. Dallabonzana D, Liuzzi A, Oppizzi G, Cozzi R, Verde G, Chiodini P, Rainer E, Dorow R, Horowski R (1986) Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J Clin Endocrinol Metab 63:1002–1007

    Article  CAS  PubMed  Google Scholar 

  25. Daughaday WH (1985) The anterior pituitary. In: Wilson JD, Foster DW (eds) Williams textbook of endocrinology, 7th edn. Saunders, Philadelphia, pp 568–613

    Google Scholar 

  26. Davis JRE, Belayew A, Sheppard MC (1988) Prolactin and growth hormone. Baillieres Clin Endocrinol Metab 2:797–834

    Article  CAS  PubMed  Google Scholar 

  27. Davis JRE, Selby C, Jeffcoate WJ (1984) Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol (Oxf) 20:427–434

    Article  CAS  Google Scholar 

  28. Davis JRE, Wilson EM, Sheppard MC (1988) Human pituitary tumours in cell culture: modulation of prolactin and growth hormone messenger RNA levels in vitro. Neuroendoc Perspect 6:221–228

    Article  Google Scholar 

  29. Day RN, Maurer RA (1989a) The distal enhancer region of the rat prolactin gene contains elements conferring response to multiple hormones. Mol Endocrinol 3:3–9

    Article  CAS  PubMed  Google Scholar 

  30. Day RN, Maurer RA (1989b) Thyroid hormone-responsive elements of the prolactin gene: evidence for both positive and negative regulation. Mol Endocrinol 3:931–938

    Article  CAS  PubMed  Google Scholar 

  31. Du LTH, Wechsler B, Seebacher J, Doumith R, Vauthier D, Darbois Y, Godeau P (1989) Adénome à prolactine au cours de la grossesse. Presse Med 18:941

    Google Scholar 

  32. Editorial (1987) When is a prolactinoma not a prolactinoma? Lancet 2:1002–1004

  33. Farkouh NH, Packer MG, Frantz HG (1979) Large molecular size prolactin with reduced receptor activity in human serum: high proportion in basal state and reduction after thyrotropin-releasing hormone. J Clin Endocrinol Metab 48:1026–1032

    Article  CAS  PubMed  Google Scholar 

  34. Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG (1989) Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 68:1201–1206

    Article  CAS  PubMed  Google Scholar 

  35. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P, Dubini A (1988) Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf) 29:467–476

    Article  CAS  Google Scholar 

  36. Fish LH, Mariash CN (1988) Hyperprolactinemia, infertility, and hypothyroidism. A case report and literature review. Arch Intern Med 148:709–711

    CAS  PubMed  Google Scholar 

  37. Fisher EC, Nelson ME, Frontera WR, Turksoy RN, Evans WJ (1986) Bone mineral content and levels of gonadotropins and estrogens in amenorrheic running women. J Clin Endocrinol Metab 62:1232–1236

    Article  CAS  PubMed  Google Scholar 

  38. Franks S, Jacobs HS (1983) Hyperprolactinemia. Clin Endocrinol Metab 12:641–668

    Article  CAS  PubMed  Google Scholar 

  39. Fraser IS, Lun ZG, Zhou JP, Herington AC, McCarron G, Caterson I, Tan K, Markham R (1989) Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 69:585–592

    Article  CAS  PubMed  Google Scholar 

  40. Garnier PE, Aubert ML, Kaplan SL, Grumbach MM (1978) Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion. J Clin Endocrinol Metab 47:1271–1281

    Article  Google Scholar 

  41. Gehlbach DL, Bayliss P, Rosa C (1989) Prolactin and thyrotropin responses to nursing during the early puerperium. J Reprod Med 34:295–298

    CAS  PubMed  Google Scholar 

  42. Gharib H, Frey HM, Laws ER, Randall RV, Scheithauer BW (1983) Coexistent primary empty sella syndrome and hyperprolactinemia. Arch Int Med 143:1383–1386

    Article  CAS  Google Scholar 

  43. Gieshoff B, Benker G, Windeck R, Reinwein D (1987) Klinisch-pathologische Konferenz: Prolaktinom und Hyperaldosteronismus bei einem 55jährigen Mann: Variante der multiplen endokrinen Adenomatose (MEA) Typ I? Med Klin 82:394

    CAS  Google Scholar 

  44. Gooren LJ, Assies J, Asscheman A, de Siegte R, van Kessel H (1988) Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab 66:444–446

    Article  CAS  PubMed  Google Scholar 

  45. Gräf KJ, Köhler D, Horowski R, Dorow R (1986) Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride. Acta Endocrinol (Copenh) 111:460–466

    Google Scholar 

  46. Gray RH, Campbell OM, Apelo R, Eslami SS, Zaccer H, Rasmos RM, Gehret JC, Labbok MH (1990) Risk of ovulation during lactation. Lancet 325:25–29

    Article  Google Scholar 

  47. Grubb MR, Chakeres D, Malarkey WB (1987) Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 83:765–769

    Article  CAS  PubMed  Google Scholar 

  48. Hwang PLH, Ng CSA, Cheong ST (1986) Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol (Oxf) 24:127–133

    Article  CAS  Google Scholar 

  49. Jackson RD, Wortsman J, Malarkey WB (1985) Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 61:258–264

    Article  CAS  PubMed  Google Scholar 

  50. Jackson RD, Wortsman J, Malarkey WB (1989) Persistence of large molecular weight prolactin secretion during pregnancy in women with macroprolactinemia and its presence in fetal cord blood. J Clin Endocrinol Metab 68:1046–1050

    Article  CAS  PubMed  Google Scholar 

  51. Judd SJ, Rigg LA, Yen SSC (1979) The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release. J Clin Endocrinol Metab 49:182–184

    Article  CAS  PubMed  Google Scholar 

  52. Jungmann E, Schwedes U, Althoff PH, Rosak C, Schöffling K (1986) Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma. Horm Metab Res 18:704–705

    Article  CAS  PubMed  Google Scholar 

  53. Koppelmann MCS, Jaffe MJ, Fieth KG, Caruso RC, Loriaux DL (1984) Hyperprolactinemia, amenorrhea, and galactorrhea. Ann Int Med 100:115–121

    Article  Google Scholar 

  54. Kovats K, Horvath E (1985) Morphology of adenohypophyseal cells and pituitary adenomas. In: Imura H (ed) The pituitary gland. Raven Press, New York, pp 25–55

    Google Scholar 

  55. Lamberts SW, Verleun T, Hofland L, Oosterom R (1986) Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 63:1342–1347

    Article  CAS  PubMed  Google Scholar 

  56. Larrea F, Villanueva C, Cravioto MC, Escorza A, Del Realo (1985) Further evidence that big-big prolactin is preferentially secreted in women with hyperprolactinemia. Fertil Steril 44:25–30

    Article  CAS  PubMed  Google Scholar 

  57. Larrea F, Escorza A, Valero A, Hernandez L, Cravioto MC, Diaz-Sanchez V (1989) Heterogeneity of serum prolactin throughout the menstrual cycle and pregnancy in hyperprolactinemic women with normal ovarian function. J Clin Endocrinol Metab 68:982–987

    Article  CAS  PubMed  Google Scholar 

  58. Laverriere JN, Morin A, Tixier-Vidal A, Truong A, Gourdji D, Martial JA (1983) Inverse control of prolactin and growth hormone gene expression: effect of thyroliberin on transcription and RNA stabilization. EMBO J 2:1493–1499

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Le Dafniet M, Grouselle D, Li JY, Kujas M, Bression D, Barret A, Tixier-Vidal A, Peillon F (1987) Evidence of thyrotropin-releasing hormone (TRH) and TRH-binding sites in human nonsecreting pituitary adenomas. J Clin Endocrinol Metab 65:1014–1019

    Article  PubMed  Google Scholar 

  60. Le Dafniet M, Brandi M, Bression D, Racadot T, Peillon F (1983) Evidence of receptors for thyrotropin-releasing hormone in human prolactin-secreting adenoma. J Clin Endocrinol Metab 57:425–427

    Article  PubMed  Google Scholar 

  61. Lecky BRF, Lightman SL, Williams TDM, Plant GT, Stevens J (1987) Myxoedema presenting with chiasmal compression: resolution after thyroxine replacement. Lancet 1:1347

    Article  CAS  PubMed  Google Scholar 

  62. Lee LR, Haisenleder DJ, Marshall JC, Smith MS (1989) The role of the suckling stimulus in regulating pituitary prolactin mRNA in the rat. Mol Cell Endocrinol 64:243–249

    Article  CAS  PubMed  Google Scholar 

  63. Lim VS, Kathpalia SC, Frohman LA (1979) Hyperprolactinemia and impaired pituitary responses to suppression and stimulation in chronic renal failure. J Clin Endocrinol Metab 48:101

    Article  CAS  PubMed  Google Scholar 

  64. Loeffler JP, Kley N, Pittius CW, Höllt V (1985) Gammaamino butyric acid decreases levels of messenger ribonucleic acid encoding prolactin in the rat pituitary. Neurosci Lett 53:121–125

    Article  CAS  PubMed  Google Scholar 

  65. Malarkey WB, Jackson R, Wortsman J (1988) Long term assessment of patients with macroprolactinemia. Fertil Steril 50:413–418

    Article  CAS  PubMed  Google Scholar 

  66. Malarkey WB, Goodenow TH, Lanese RR (1980) Diurnal variation of prolactin secretion differentiates pituitary tumors from primary empty sella syndrome. Am J Med 89:886

    Article  Google Scholar 

  67. March CM, Kletzky OA, Davajan V (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139:835

    Article  CAS  PubMed  Google Scholar 

  68. Markoff E, Lee DW (1987) Glycosylated prolactin is a major circulating variant in human serum. J Clin Endocrinol Metab 65:1102–1106

    Article  CAS  PubMed  Google Scholar 

  69. Marshall LA, Martin MC, Leong S, Jaffe RB (1988) Influence of preovulatory estradiol concentration on diurnal and pulsatile prolactin secretion patterns. Am J Obstet Gynecol 159:1558–1563

    Article  CAS  PubMed  Google Scholar 

  70. Martin TL, Kim M, Malarkey WB (1985) The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 60:855–858

    Article  CAS  PubMed  Google Scholar 

  71. Mattox JH, Fortunato SJ (1986) Prolactin response to perphenazine. A sensitive and specific test for pituitary tumor in hyperprolactinemic women. J Reprod Med 31:1098–1110

    CAS  PubMed  Google Scholar 

  72. Maurer RA (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294:94–97

    Article  CAS  PubMed  Google Scholar 

  73. Melmed S, Braunstein GD, Chang J, Becker DP (1986) Pituitary tumors secreting growth hormone and prolactin. Ann Int Med 105:238–253

    Article  CAS  PubMed  Google Scholar 

  74. Melmed S (1983) Isolation of human-mouse somatic cell hybrids secreting human prolactin: dominant expression of hormone secretion and regulation. J Clin Endocrinol Metab 56:1145–1151

    Article  CAS  PubMed  Google Scholar 

  75. Memo M, Castelletti L, Missale C, Valerio A, Carruba M, Spano PF (1986) Dopaminergic inhibition of prolactin release and calcium influx induced by neurotensin in anterior pituitary is independent of cyclic AMP system. J Neurochem 47:1689–1695

    Article  CAS  PubMed  Google Scholar 

  76. Mendelson JH, Mello NK, Teok SK, Ellinghoe J, Cochin L (1989) Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69:1256–1260

    Article  CAS  PubMed  Google Scholar 

  77. Miller WL, Eberhardt NL (1983) Structure and evolution of the growth hormone gene family. Endocr Rev 4:97–130

    Article  CAS  PubMed  Google Scholar 

  78. Molitch ME, Hou SH (1983) Neuroendocrine alterations in systemic disease. Clin Endocrinol Metab 12:825–851

    Article  CAS  PubMed  Google Scholar 

  79. Nicoletti I, Ambrosi F, Pagliacci MC, Pelicci G, Giammartino C, Maggio D, Fedeli L, Filipponi P (1987) Catecholamines and pituitary function. VI. Effect of different dopamine doses on TRH-induced prolactin release in women with pathological hyperprolactinemia. Horm Metab Res 19:125–129

    Article  CAS  PubMed  Google Scholar 

  80. Nikolics K, Mason AJ, Szonyi E, Ramachandran R, Seeburg PH (1985) A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 316:511–517

    Article  CAS  PubMed  Google Scholar 

  81. Owerbach D, Rutter WJ, Cooke NE, Martial JA, Shows TB (1981) The prolactin gene is located on chromosome 6 in humans. Science 212:813–816

    Article  Google Scholar 

  82. Panteon E, Loumaye E, Maes M, Malvaux P (1988) Occurrence of prolactinoma after estrogen treatment in a girl with constitutional tall stature. J Pediatr 113:337–933

    Article  CAS  PubMed  Google Scholar 

  83. Peces R, Horcajada C, Lopez-Nuova JM, Frutos MA, Casado S, Hernando L (1981) Hyperprolactinemia in chronic renal failure: impaired responsiveness to stimulation and suppression. Nephon 28:1

    Google Scholar 

  84. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509

    Article  CAS  PubMed  Google Scholar 

  85. Pereira MC, Sobrinho LG, Afonso AM, Ferreira JM, Santos AM, Sousa MF (1987) Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma? Obstet Gynecol 70:305–308

    CAS  PubMed  Google Scholar 

  86. Pfingsten H, Haase R, Windeck R, Reinhardt W, Jaspers C, Lancranjan I, Benker G, Reinwein D (1989) Effect of a long-acting injectable dopamine agonist on serum growth hormone levels in acromegaly. Acta Endocrinol (Copenh) 120:79

    Google Scholar 

  87. Pichon MF, Bression D, Peillon F, Milgrom E (1980) Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metab 51:897

    Article  CAS  PubMed  Google Scholar 

  88. Pioro EP, Scheithauer BW, Laws ER, Randall RV, Kovacs KT, Horvath E (1988) Combined thyrotroph and lactotroph cell hyperplasia simulating prolactin-secreting pituitary adenoma in long-standing primary hypothyroidism. Surg Neurol 29:218–226

    Article  CAS  PubMed  Google Scholar 

  89. Pontiroli AE, Baio G, Stella L, Crescenti A, Girardi AM (1982) Effects of naloxone on prolactin, luteinizing hormone, and cortisol responses to surgical stress in humans. J Clin Endocrinol Metab 55:378–380

    Article  CAS  PubMed  Google Scholar 

  90. Prager D, Yamashita S, Melmed S (1988) Insulin regulates prolactin secretion and messenger ribonucleic acid levels in pituitary cells. Endocrinology 122:2946–2952

    Article  CAS  PubMed  Google Scholar 

  91. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactinproducing marcroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64:391–394

    Article  CAS  PubMed  Google Scholar 

  92. Ramirez G, O'Neill WM, Bloomer MA, Jubiz W (1977) Abnormalities in the regulation of prolactin in patients with chronic renal failure. J Clin Endocrinol Metab 45:658

    Article  CAS  PubMed  Google Scholar 

  93. Rasmussen C, Bergh T, Wide L, Brownell J (1988) Longterm treatment with a new non-ergot long-acting dopamine agonist, CV 205–502, in women with hyperprolactinemia. Clin Endocrinol (Oxf) 29:271–279

    Article  CAS  Google Scholar 

  94. Reichlin S (1985) Neuroendocrinology. In: Wilson JD, Foster DW (eds) Williams textbook of endocrinology, 7th edn. Saunders, Philadelphia, pp 568–613

    Google Scholar 

  95. Rogol AD, Rosen SW (1984) Prolactin of apparent large molecular size: the major immunoreactive component in plasma of a patient with a pituitary tumor. J Clin Endocrinol Metab 38:714–717

    Article  Google Scholar 

  96. Ruberg M, Rotsztein WH, Arancibia S, Besson J, Enjalbert A (1978) Stimulation of prolactin release by vasoactive intestinal peptide (VIP). Eur J Pharmacol 51:319–320

    Article  CAS  PubMed  Google Scholar 

  97. Rubio MA, Cabranes JA, Schally AV, Charro AL (1989) Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients. J Clin Endocrinol Metab 69:444–447

    Article  CAS  PubMed  Google Scholar 

  98. Sasaki A, Sato S, Shinkawa O, Go M, Otsuka T, Sugawara A, Shimizu Y, Murakami O, Hanew K, Andoh N, Sasano N, Yoshinaga K (1988) Peptide histidine methionine may be a prolactin-releasing hormone in humans. J Clin Endocrinol Metab 66:1202–1207

    Article  CAS  PubMed  Google Scholar 

  99. Scanlon MF, Peters JR, Salvadorf J, Richards SH, John R, Howell S, Williams ED, Thomas JP, Hall R (1986) The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size. Clin Endocrinol (Oxf) 24:435–446

    Article  CAS  Google Scholar 

  100. Scanlon MF, Rodriguez-Armao MD, McGregor AM, Weightman DR, Lewis M, Cock DB, Gomez-Pan A, Hall R (1981) Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin Endocrinol (Oxf) 14:133

    Article  CAS  Google Scholar 

  101. Schechter J, Goldsmith O, Wilson C, Weiner R (1988) Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab 67:713–719

    Article  CAS  PubMed  Google Scholar 

  102. Scheithauer BW, Kovacs KT, Randall RV, Ryan N (1989) Effects of estrogen on the human pituitary: a clinicopathologic study. Mayo Clin Proc 64:1077–1084

    Article  CAS  PubMed  Google Scholar 

  103. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418

    Article  CAS  PubMed  Google Scholar 

  104. Serri D, Robert F, Comtois R, Jilwan N, Beauregard H, Hardy J, Somma M (1987) Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinemia. Clin Endocrinol (Oxf) 27:429–436

    Article  CAS  Google Scholar 

  105. Shangold MM, Gatz ML, Thysen B (1981) Acute effects of exercise on plasma concentrations of prolactin and testosterone in recreational women runners. Fertil Steril 35:699–702

    Article  CAS  PubMed  Google Scholar 

  106. Shivers BD, Harlan RE, Pfaff DW (1989) A subset of neurons containing immunoreactive prolactin is a target for estrogen regulation of gene expression in rat hypothalamus. Neuroendocrinology 49:23–27

    Article  CAS  PubMed  Google Scholar 

  107. Sinha YN, Jacobsen BP (1988) Three growth hormone-and two prolactin-related novel peptides of Mw 13,000–18,000 identified in the anterior pituitary. Biochem Biophys Res Commun 156:171–179

    Article  CAS  PubMed  Google Scholar 

  108. Sisam DA, Sheehan JP, Sheeler LR (1987) The natural history of untreated microprolactinomas. Fertil Steril 48:67

    Article  CAS  PubMed  Google Scholar 

  109. Sisam DA, Sheehan JP, Schumacher OP (1986) Lack of demonstrable tumor growth in progressive hyperprolactinemia. Am J Med 80:279–280

    Article  CAS  PubMed  Google Scholar 

  110. Smith KW, Howard CP, Allphin BJ, Grunt JA (1988) The influence of oral contraceptives on hormonal and metabolic homeostasis in young adolescents. J Adolesc Health Care 9:488–490

    Article  CAS  PubMed  Google Scholar 

  111. Soong YK, Ferguson KM, McGarnick G, Jeffcoate SL (1982) Size heterogeneity in immunoactive prolactin in hyperprolactinemic serum. Clin Endocrinol (Oxf) 16:259–265

    Article  CAS  Google Scholar 

  112. Steel JH, Hamid Q, van Noorden S (1988) Combined use of in situ hybridization and immuncytochemistry for the investigation of prolactin gene expression in immature, pubertal, pregnant, lactating and ovariectomised rats. Histochemistry 89:75–80

    Article  CAS  PubMed  Google Scholar 

  113. Supowit SC, Potter E, Evans RM, Rosenfeld MG (1981) Polypeptide hormone regulation of gene transcription: specific 5′ genomic sequences are required for epidermal growth factor and phorbol ester regulation of prolactin gene expression. Proc Natl Acad Sci USA 81:2975–2979

    Article  Google Scholar 

  114. Thomas DJB, Touzel R, Charlesworth M, Wass JAH, Besser GM (1987) Hyperprolactinaemia and microadenomas in primary hypothyroidism. Clin Endocrinol (Oxf) 27:289

    Article  CAS  Google Scholar 

  115. Travaglini P, Moriondo P, Togni E, Venegoni P, Bochicchio D, Conti A, Ambroso G, Ponticelli C, Mocchegiani E, Fabris N, Faglia G (1989) Effect of oral zinc administration on prolactin and thymulin circulatory levels in patients with chronic renal failure. J Clin Endocrinol Metab 68:186–190

    Article  CAS  PubMed  Google Scholar 

  116. van't Verlaat JW, Lancranjan I, Hendriks MJ, Croughs RJ (1988) Primary treatment of macroprolactinomas with Parlodel LAR. Acta Endocrinol (Copenh) 19:51–55

    Google Scholar 

  117. van Loon GR (1978) A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma. Lancet 2:686

    Google Scholar 

  118. Vance ML, Thorner MO (1987) Prolactinomas. Endocrinol Metab Clin North Amer 16:731–753

    CAS  Google Scholar 

  119. Vance ML, Evans WS, Thorner MO (1984) Bromocriptine. Ann Int Med 100:78–91

    Article  CAS  PubMed  Google Scholar 

  120. Vance ML, Cragun JR, Reinmitz C, Chang RJ, Rashef E, Blackwell RE, Miller MM, Molitch ME (1989) CV 205–502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 68:336–339

    Article  CAS  PubMed  Google Scholar 

  121. Veldhuis JD, Johnson ML (1988) Operating characteristics of the hypothalmo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab 67:116–123

    Article  CAS  PubMed  Google Scholar 

  122. Vetekemans M, Robyn C (1985) The influence of exogenous estrogen on the circadian periodicity of circulating prolactin in women. J Clin Endocrinol Metab 40:886–889

    Article  Google Scholar 

  123. Waddington JL, O'Boyle, KM (1989) Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D1-antagonist. Pharmac Ther 43:1–52

    Article  CAS  Google Scholar 

  124. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, Moore JW, Fentiman IS, Hayward JL, Gravelle IH (1988) The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 24:1225–1231

    Article  CAS  PubMed  Google Scholar 

  125. Wark JD, Tashjian AH (1983) Regulation of prolactin mRNA by 1,25-dihydroxyvitamin D3 in GH4C1 cells. J Biological Chem 258:12118–12121

    CAS  Google Scholar 

  126. Waterman ML, Adler S, Nelson C, Greene GL, Evans RM, Rosenfeld MG (1988) A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. Mol Endocrinol 2:14–21

    Article  CAS  PubMed  Google Scholar 

  127. Whittaker PG, Wilcox T, Lind T (1981) Maintained fertility in a patient with hyperprolactinemia due to “big big” prolactin. J Clin Endocrinol Metab 53:863–866

    Article  CAS  PubMed  Google Scholar 

  128. Wood PL, Altar CA (1988) Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 40:163–187

    CAS  PubMed  Google Scholar 

  129. Zarate A, Canales ES (1987) Endocrine aspects of lactation and postpartum infertility. J Steroid Biochem 27:1023–1028

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Endokrinologie, Medizinische Klinik und Poliklinik, Universität Essen, Deutschland

    G. Benker, C. Jaspers & D. Reinwein

  2. Abteilung für Pharmakologie, E. Merck, Darmstadt

    G. Häusler

  3. Department ZWD, E. Merck, Frankfurter Str. 250, W-6100, Darmstadt, FRG

    G. Benker

Authors
  1. G. Benker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Jaspers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Häusler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Reinwein
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Presented in part to the European Society for Clinical Investigation, Maastricht, April 27, 1990

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benker, G., Jaspers, C., Häusler, G. et al. Control of prolactin secretion. Klin Wochenschr 68, 1157–1167 (1990). https://doi.org/10.1007/BF01815271

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01815271

Key words

Search

Navigation